Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2025
0mins
Should l Buy CRSP?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones dropping approximately 350 points, while several companies like Gilead Sciences and Upstart Holdings saw significant gains due to better-than-expected financial results.
Notable Stock Increases: Gilead Sciences' shares rose 8.1% after reporting strong earnings, while other companies such as Upstart Holdings (up 30.7%) and AnaptysBio (up 19.6%) also experienced substantial increases following positive quarterly results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 48.930
Low
50.00
Averages
78.89
High
105.00
Current: 48.930
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics: A Biotech Stock Poised for Growth
- Gene Editing Leader: CRISPR Therapeutics stands out as a leader in gene editing, utilizing CRISPR technology to repair specific genes for disease treatment, having secured the first-ever FDA approval for its CRISPR product, Casgevy, marking a significant breakthrough in the biotech industry.
- Massive Market Potential: The launch of Casgevy is gaining momentum, with CRISPR Therapeutics stating that the product has 'multi-billion-dollar potential'; although profits are shared with partner Vertex Pharmaceuticals, it still represents substantial growth opportunities for the company.
- Catalysts in 2026: The company expects to release clinical trial updates for cardiovascular candidate CTX310 and thromboembolic candidate CTX611 in the second half of 2026, along with trials for refractory hypertension and lung/liver disease, which could provide short-term stock support.
- Long-Term Growth Outlook: With a robust pipeline and the success of Casgevy, CRISPR Therapeutics is well-positioned for long-term growth, making it a stock that investors may regret missing out on in 2026.
See More
CRISPR Therapeutics Shows Growth Potential
- Technological Breakthrough: CRISPR Therapeutics received FDA approval for its first CRISPR product, Casgevy, marking a successful application of gene editing technology, which is expected to generate multi-billion-dollar revenue potential and further solidify its leadership in the biotech sector.
- Product Launch Progress: The market launch of Casgevy is gaining momentum, and although profits are shared with partner Vertex Pharmaceuticals, it still presents significant growth opportunities for CRISPR Therapeutics, reflecting the company's innovative capabilities in treating blood disorders.
- Future Catalysts: Multiple clinical trial updates are expected in the second half of 2026, including cardiovascular candidate CTX310 and thromboembolic candidate CTX611, which could provide short-term support for the stock price and enhance investor confidence.
- Pipeline Development: CRISPR Therapeutics plans to initiate clinical trials for refractory hypertension candidates in the first half of 2026 and for lung and liver disease candidates in mid-2026, establishing a robust product pipeline that lays a solid foundation for long-term growth.
See More
CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings
- Disappointing Earnings: CRISPR Therapeutics reported only $864,000 in revenue for Q4, resulting in a loss of $1.37 per share, significantly worse than analysts' expectations of a $1.20 loss, highlighting ongoing financial struggles.
- Partner Support: Despite CRISPR's poor revenue, its partner Vertex Pharmaceuticals anticipates over $500 million in revenue from non-cystic fibrosis products in 2026, indicating that CRISPR's gene-editing therapy Casgevy may achieve greater market potential in the future.
- Positive Market Reaction: CRISPR's stock rose 9.7% on Friday despite the disappointing earnings report, reflecting market optimism about its long-term growth potential, particularly in the innovative gene-editing sector.
- Future Outlook: Analysts project CRISPR's revenue to reach nearly $130 million in 2026, a significant increase from $3.5 million in 2025, although the company remains unprofitable, indicating market confidence in its product pipeline.
See More
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
CRISPR Therapeutics Reports Q4 Losses Amid Revenue Decline
- Earnings Miss: CRISPR Therapeutics reported a Q4 GAAP EPS of -$1.37, missing estimates by $0.22, indicating significant challenges in achieving profitability.
- Revenue Plunge: The company’s Q4 revenue of $0.86 million represents a staggering 97.6% year-over-year decline, falling short of expectations by $3.16 million, highlighting a sharp decrease in market demand for its products.
- Strong Cash Position: As of December 31, 2025, CRISPR held $1,975.8 million in cash, cash equivalents, and marketable securities, up from $1,903.8 million a year earlier, reflecting a solid liquidity management strategy.
- Market Reaction: Despite the disappointing earnings report, CRISPR Therapeutics managed to pare losses amid takeover speculation, suggesting that investors are attentive to potential restructuring or strategic shifts in the company’s future.
See More
Cathie Wood's Investment Outlook for 2026
- Joby Aviation Investment: Despite Joby Aviation's stock plummeting 17% after announcing a $1.2 billion stock and convertible note offering, it still achieved a 33% return over the past year, indicating market confidence in the long-term potential of electric vertical takeoff and landing aircraft, with Wood's increased stake signaling her bullish outlook.
- Kodiak AI Challenges: Kodiak AI's market cap has dropped from $2.5 billion to $1.6 billion, and while its technology in autonomous trucking is promising, the current operation of only 10 commercial vehicles suggests insufficient market acceptance, making Wood's investment a bet on future growth potential.
- CRISPR Therapeutics Outlook: CRISPR set multiple milestones for 2026, with its Casgevy treatment generating over $100 million in revenue last year; despite its stock being down 76% from its all-time high five years ago, plans to expand treatment usage may attract renewed investor interest.
- Market Sentiment Analysis: Wood's decision to increase her holdings during market downturns reflects her confidence in long-term growth, and despite facing stock price volatility and market concerns in the short term, her investment strategy may yield substantial returns in the future.
See More
CRISPR Therapeutics: A Biotech Stock Poised for Growth
- Gene Editing Leader: CRISPR Therapeutics stands out as a leader in gene editing, utilizing CRISPR technology to repair specific genes for disease treatment, having secured the first-ever FDA approval for its CRISPR product, Casgevy, marking a significant breakthrough in the biotech industry.
- Massive Market Potential: The launch of Casgevy is gaining momentum, with CRISPR Therapeutics stating that the product has 'multi-billion-dollar potential'; although profits are shared with partner Vertex Pharmaceuticals, it still represents substantial growth opportunities for the company.
- Catalysts in 2026: The company expects to release clinical trial updates for cardiovascular candidate CTX310 and thromboembolic candidate CTX611 in the second half of 2026, along with trials for refractory hypertension and lung/liver disease, which could provide short-term stock support.
- Long-Term Growth Outlook: With a robust pipeline and the success of Casgevy, CRISPR Therapeutics is well-positioned for long-term growth, making it a stock that investors may regret missing out on in 2026.
See More
CRISPR Therapeutics Shows Growth Potential
- Technological Breakthrough: CRISPR Therapeutics received FDA approval for its first CRISPR product, Casgevy, marking a successful application of gene editing technology, which is expected to generate multi-billion-dollar revenue potential and further solidify its leadership in the biotech sector.
- Product Launch Progress: The market launch of Casgevy is gaining momentum, and although profits are shared with partner Vertex Pharmaceuticals, it still presents significant growth opportunities for CRISPR Therapeutics, reflecting the company's innovative capabilities in treating blood disorders.
- Future Catalysts: Multiple clinical trial updates are expected in the second half of 2026, including cardiovascular candidate CTX310 and thromboembolic candidate CTX611, which could provide short-term support for the stock price and enhance investor confidence.
- Pipeline Development: CRISPR Therapeutics plans to initiate clinical trials for refractory hypertension candidates in the first half of 2026 and for lung and liver disease candidates in mid-2026, establishing a robust product pipeline that lays a solid foundation for long-term growth.
See More
CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings
- Disappointing Earnings: CRISPR Therapeutics reported only $864,000 in revenue for Q4, resulting in a loss of $1.37 per share, significantly worse than analysts' expectations of a $1.20 loss, highlighting ongoing financial struggles.
- Partner Support: Despite CRISPR's poor revenue, its partner Vertex Pharmaceuticals anticipates over $500 million in revenue from non-cystic fibrosis products in 2026, indicating that CRISPR's gene-editing therapy Casgevy may achieve greater market potential in the future.
- Positive Market Reaction: CRISPR's stock rose 9.7% on Friday despite the disappointing earnings report, reflecting market optimism about its long-term growth potential, particularly in the innovative gene-editing sector.
- Future Outlook: Analysts project CRISPR's revenue to reach nearly $130 million in 2026, a significant increase from $3.5 million in 2025, although the company remains unprofitable, indicating market confidence in its product pipeline.
See More
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
CRISPR Therapeutics Reports Q4 Losses Amid Revenue Decline
- Earnings Miss: CRISPR Therapeutics reported a Q4 GAAP EPS of -$1.37, missing estimates by $0.22, indicating significant challenges in achieving profitability.
- Revenue Plunge: The company’s Q4 revenue of $0.86 million represents a staggering 97.6% year-over-year decline, falling short of expectations by $3.16 million, highlighting a sharp decrease in market demand for its products.
- Strong Cash Position: As of December 31, 2025, CRISPR held $1,975.8 million in cash, cash equivalents, and marketable securities, up from $1,903.8 million a year earlier, reflecting a solid liquidity management strategy.
- Market Reaction: Despite the disappointing earnings report, CRISPR Therapeutics managed to pare losses amid takeover speculation, suggesting that investors are attentive to potential restructuring or strategic shifts in the company’s future.
See More
Cathie Wood's Investment Outlook for 2026
- Joby Aviation Investment: Despite Joby Aviation's stock plummeting 17% after announcing a $1.2 billion stock and convertible note offering, it still achieved a 33% return over the past year, indicating market confidence in the long-term potential of electric vertical takeoff and landing aircraft, with Wood's increased stake signaling her bullish outlook.
- Kodiak AI Challenges: Kodiak AI's market cap has dropped from $2.5 billion to $1.6 billion, and while its technology in autonomous trucking is promising, the current operation of only 10 commercial vehicles suggests insufficient market acceptance, making Wood's investment a bet on future growth potential.
- CRISPR Therapeutics Outlook: CRISPR set multiple milestones for 2026, with its Casgevy treatment generating over $100 million in revenue last year; despite its stock being down 76% from its all-time high five years ago, plans to expand treatment usage may attract renewed investor interest.
- Market Sentiment Analysis: Wood's decision to increase her holdings during market downturns reflects her confidence in long-term growth, and despite facing stock price volatility and market concerns in the short term, her investment strategy may yield substantial returns in the future.
See More
